Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN ULTRA versus MYCELEX 7 COMBINATION PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN ULTRA versus MYCELEX 7 COMBINATION PACK.
GRISACTIN ULTRA vs MYCELEX-7 COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to tubulin and disrupts microtubule function, inhibiting fungal cell division and nucleic acid synthesis.
Clotrimazole, an imidazole antifungal, inhibits cytochrome P450 14α-demethylase (CYP51), thereby blocking ergosterol synthesis in fungal cell membranes, increasing membrane permeability and causing cell death. Miconazole, also an imidazole, similarly inhibits CYP51, disrupting ergosterol synthesis.
500 mg orally once daily or 250 mg orally twice daily; for severe infections, 500 mg twice daily or 250 mg three times daily. Maximum daily dose: 1 g. Administer with or after meals.
Clotrimazole vaginal cream 1%: one applicatorful (approximately 5 g) intravaginally at bedtime for 7 consecutive days. Clotrimazole vaginal tablets 100 mg: one tablet intravaginally at bedtime for 7 consecutive days.
None Documented
None Documented
Terminal elimination half-life ranges from 6.5 to 9 hours (mean ~7.5 hours) in patients with normal hepatic function; prolonged in hepatic impairment.
Topical clotrimazole has a terminal elimination half-life of 3-6 hours; systemic absorption is minimal, so half-life is not clinically relevant for local effects.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; approximately 30-50% of a dose is eliminated in feces as metabolites, with minor biliary excretion.
Clotrimazole is primarily excreted via feces (approximately 65%) as metabolites and unchanged drug; renal excretion accounts for less than 1% after topical administration. Biliary excretion is negligible.
Category C
Category C
Antifungal
Antifungal